Molecules that home to various selected organs or tissues

An isolated peptidomimetic, comprising the sequence SMSIARL (SEQ ID NO:21),

• wherein said peptidomimetic selectively homes to the vasculature of the prostate.

A conjugate, comprising a peptide comprising the sequence SMSIARL (SEQ ID NO:

• 21),
• wherein said peptide is linked to a moiety and said peptide selectively homes to the vasculature of the prostate.

A conjugate, comprising a peptidomimetic comprising the sequence SMSIARL (SEQ ID NO:21),

• wherein said peptidomimetic is linked to a moiety and said peptidomimetic selectively homes to the vasculature of the prostate.

An isolated peptide, comprising the sequence VSFLEYR (SEQ ID NO:

• 22) and having at most 100 residues,
• wherein said peptide selectively homes to the vasculature of the prostate.

An isolated peptidomimetic, comprising the sequence VSFLEYR (SEQ ID NO:22),

• wherein said peptidomimetic selectively homes to the vasculature of the prostate.

A method of identifying prostate tissue, comprising the steps of:

• a) contacting a tissue or organ with an isolated peptide that selectively homes to the vasculature of the prostate comprising the sequence VSFLEYR (SEQ ID NO:22);
• and
• b) detecting binding of said peptide to said organ or tissue, thereby identifying the organ or tissue as prostate tissue.

A conjugate, comprising a peptide comprising the sequence VSFLEYR (SEQ ID NO:

• 22) and having at most 100 residues,
• wherein said peptide is linked to a moiety and said peptide selectively homes to vasculature of the prostate.

A conjugate, comprising a peptidomimetic comprising the sequence VSFLEYR (SEQ ID NO:22),

• wherein said peptidomimetic is linked to a moiety and said peptidomimetic selectively homes to the vasculature of the prostate.

A method of treating a prostate pathology in a subject, comprising administering to the subject a conjugate comprising a peptide comprising the sequence VSFLEYR (SEQ ID NO:22) linked to a moiety, wherein said peptide selectively homes to prostate, thereby treating the prostate pathology.

An isolated peptide, comprising the sequence RGRWLAL (SEQ ID NO:

• 279),
• wherein said peptide selectively homes to the vasculature of the prostate.

An isolated peptidomimetic, comprising the sequence RGRWLAL (SEQ ID NO:279),

• wherein said peptidomimetic selectively homes to the vasculature of the prostate.

A conjugate, comprising a peptide comprising the sequence RGRWLAL (SEQ ID NO:

• 279),
• wherein said peptide is linked to a moiety and said peptide selectively homes to the vasculature of the prostate.

A conjugate, comprising a peptidomimetic comprising the sequence RGRWLAL (SEQ ID NO:

• 279),
• wherein said peptidomimetic is linked to a moiety and said peptidomimetic selectively homes to the vasculature of the prostate.

An isolated peptide, comprising an amino acid sequence having, 6 to 100 residues,

• wherein said peptide selectively homes to the vasculature of the prostate.

An isolated peptide that selectively homes to the vasculature of the prostate, provided that said peptide is not an antibody or antigen-binding fragment thereof.

An isolated single-chain peptide that selectively homes to the vasculature of the prostate.